Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Search
Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
Ivermectin in Animal Health products and COVID-19
Ivermectin in Animal Health products and COVID-19
Financial year 2018
Financial year 2018
Ridgefield, CT | BI Facilities
BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim
BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.
Shelter Revamps Make for Strong Bonds, More Adoptions
Shelter Revamps Make for Strong Bonds, More Adoptions
Connecting our employees to nonprofits that help people around the world
Learn about the new online tool that we’re using to help our employees connect with nonprofits that are providing critical services to communities, choose volunteer activities in their field, and lend their expertise to those in need.
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.
A day of giving back at Pegasus Therapeutic Riding
Take a look at our volunteer day spent refreshing a farm committed to equine therapy.
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim and Vanderbilt University join forces
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Helping pets in hurricane-ravaged Puerto Rico
Helping pets in hurricane-ravaged Puerto Rico
World Water Day 2019 | Boehringer Ingelheim US
Click here to find out more on the steps Boehringer Ingelheim are taking on World Water Day 2019 to support animal shelters in Mexico City.
African Swine Fever: Important Facts | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.
BI USA Recognized as Best Place to Work for LGBTQ+ Equality
BI USA Recognized as Best Place to Work for LGBTQ+ Equality
HEARTGARD Plus Save A Heart Initiative | Boehringer Ingelheim US
See how Boehringer Ingelheim, the maker of HEARTGARD Plus, is flying at risk dogs to new homes across the US to celebrate Heartworm Disease Awareness Month
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim US Veterinary Scholars Program Profiles | Boehringer Ingelheim US
Click here to find out more how the Boehringer Ingelheim veterinary scholars program has helped 3,500 people over 30 years. Read five of their stories here.
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing
Championing for people with all abilities
Every diverse background brings unique perspectives to our company.
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Championing minds for generations both in and out of the workplace
Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.